India has approved its first dengue vaccine, with the Drug Controller General of India (DCGI) granting market authorisation to QDENGA, developed by Takeda Biopharmaceuticals India.
The clearance allows the vaccine to be rolled out in a country that records some of the world’s highest dengue caseloads each year. QDENGA is designed to protect against multiple serotypes of the dengue virus, which is spread by Aedes mosquitoes and can cause severe, sometimes fatal, illness.
The approval is being closely watched across South Asia, where dengue is endemic and seasonal outbreaks strain hospital systems. Sri Lanka is currently battling a severe dengue season of its own, with cases well above 75,000 and dozens of deaths reported this year.
There is no specific antiviral treatment for dengue, so prevention has relied heavily on mosquito control, public awareness and clinical management of cases. A licensed vaccine offers health authorities an additional tool, though experts note that rollout, pricing and eligibility criteria will determine its real-world impact.
Regional health officials are expected to study India’s approval process and QDENGA’s performance data as they weigh options for their own dengue-control strategies.
